A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
AIMS: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used drugs with applications beyond the management of obesity and diabetes mellitus. This study aimed to investigate the association between GLP-1 RA use and hair loss. METHODS: F…
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 25% of the global population, with limited pharmacological treatment options. While lifestyle modification remains foundational, nanomedicine offers promising stra…
AIMS: We aimed to examine the association between GLP-1 RA use and suicidal ideation or behaviours through a systematic review of observational studies. MATERIALS AND METHODS: A comprehensive search of MEDLINE, PubMed, EMBASE, CINAHL and PsycINFO was…
52-year-old woman with cardiac sarcoidosis and a dual-chamber implantable cardioverter defibrillator (ICD) was treated with semaglutide for refractory obesity (body mass index (BMI) of 40.1 (kg/m)). After rapid weight loss of 25 kg, she developed pai…
GLP-1 receptor agonist (GLP-1RA) discontinuation has been associated with weight regain. However, weight trajectories following the last documented GLP-1RA prescription in the real-world clinical setting have not been explored. Here, we assessed weig…
BACKGROUND: Laboratory changes after antiobesity drugs in routine care are not well-described. STUDY QUESTION: In adults with obesity and no diabetes, how do 2-year laboratory trends and major clinical outcomes compare after starting semaglutide vers…
OBJECTIVES: This study aimed to identify key regulatory genes involved in chondrocyte senescence in osteoarthritis (OA) and to evaluate the therapeutic potential of the GLP-1 receptor agonist semaglutide. METHODS: Transcriptomic data of chondrocytes…
BACKGROUND: Dumping syndrome and reactive hypoglycemia are common complications after bariatric surgery, particularly Roux-en-Y gastric bypass (RYGB). Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has emerged as a potential therape…
BACKGROUND: A patient-reported outcome measure (PROM) is needed to study facial appearance in the context of rapid weight loss following use of anti-obesity medications. Such treatments can cause sunken cheeks, hollow eyes, saggy skin and an aged app…
OBJECTIVE: To compare the real-world efficacy and safety of high dose once-weekly glucagon-like peptide-1 receptor agonists polyethylene glycol loxenatide (PEG-Loxe) and subcutaneous (s.c.) semaglutide in patients with suboptimally controlled type 2…
AIMS: To evaluate glycemic control, weight management, and patient-reported outcomes (PROs) in adults with type 2 diabetes mellitus who transitioned to oral semaglutide (OS) after inadequate glycemic control on dipeptidyl peptidase-4 inhibitors (DPP-…
PURPOSE: The Inflation Reduction Act (IRA) introduced significant reforms to Medicare Part D in 2025, aiming to reduce medication costs for beneficiaries by eliminating the coverage gap ("donut hole") with a $2,000 annual out-of-pocket cap. However,…
OBJECTIVES: We reviewed weight loss and gaining wrinkles, and the impact of weight loss drugs on facial aesthetics. METHODS: The resources from Eskişehir Osmangazi and Kirikkale Universities, along with Google, Google Scholar, PubMed, EBSCO, and ProQ…
INTRODUCTION: Mitochondrial diabetes is rare and typically treated with dietary intervention and oral hypoglycaemic agents. Most require insulin. Novel treatments are available but are not well-characterised. PRESENTATION: A 16-year-old adolescent gi…
PURPOSE: This study evaluated the cost-effectiveness (from the United States [US] societal perspective) of tirzepatide at its maximum-tolerated-dose (MTD) compared to semaglutide (MTD), both administered adjunct to a reduced-calorie diet and increase…
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a novel class of glucose-lowering agents that offer benefits beyond glycemic control and weight loss and are increasingly recognized for their cardioprotective benefits, including protective ef…
BACKGROUND: Obesity is linked to cardiometabolic risk, and semaglutide, a glucagon-like peptide-1 receptor agonist, has emerged as a promising option for weight and metabolic control. This systematic review and meta-analysis evaluated the effects of…
OBJECTIVE: Semaglutide (SMG), a clinically relevant peptide-based therapeutic whose physical and chemical stability are critical concerns during manufacturing and storage. Although the stability of SMG in solution has been extensively studied, its so…
Obesity is a growing global health concern that leads to metabolic imbalances and progressive cardiac remodelling. This study investigated whether semaglutide (SMG) can counteract the disruption to the gut-heart-metabolic axis and associated myocardi…
BACKGROUND: The comparative gastrointestinal safety across glucagon-like peptide-1 receptor agonists and tirzepatide is still unclear. OBJECTIVE: To compare the risk for severe gastrointestinal adverse events across dulaglutide, subcutaneous semaglut…